Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Efficacy is variant dependent. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Casadevall, Choudhary, Günther, Leducq.
Recent:Evering Casadevall.
Amubarvimab/romlusevimab was adopted
in 1 country.
Submit updates/corrections .
Summary.
Oct 4 |
Amubarvimab/romlusevimab for COVID-19: real-time meta analysis of 3 studies | |
| Statistically significant lower risk is seen for viral clearance. 2 studies from 2 independent teams (both from the same country) show significant improvements. Meta analysis using the most serious outcome reported shows 18% [-156.. | ||
Aug 16 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102787 | Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial |
| 91% lower mortality (p=0.006), 20% higher PASC (p=0.39), 61% lower hospitalization (p=0.0008), and 67% lower combined mortality/hospitalization (p<0.0001). RCT 780 high-risk non-hospitalized COVID-19 patients showing significantly lower risk of hospitalization or death through 36 weeks, but no significant difference in long COVID with amubarvimab/romlusevimab treatment compared to placebo. | ||
Aug 11 |
, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268 | Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities |
| Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date. | ||
Aug 8 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408 | Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship |
| Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod.. | ||
Apr 19 |
et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-024-00753-7 | Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study |
| 71% higher mortality (p=0.35), 8% higher ICU admission (p=0.8), 8% shorter hospitalization (p=0.004), and 7% faster viral clearance (p=0.004). Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy fo.. | ||
Sep 6 2022 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.983505 | Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults |
| Phase 1 RCT with 44 healthy adults showing BRII-196 and BRII-198 monoclonal antibodies, alone or in combination, were safe and well-tolerated up to the highest doses tested of 3,000 mg for single mAbs and 1500/1500 mg for the combination... | ||
Dec 23 2021 |
et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00751-9 | Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial |
| 15% higher mortality (p=0.72) and 7% improved recovery (p=0.48). RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.